{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T16:01:23Z","timestamp":1720627283666},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T00:00:00Z","timestamp":1467158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ijid.2016.06.020","type":"journal-article","created":{"date-parts":[[2016,7,2]],"date-time":"2016-07-02T23:46:01Z","timestamp":1467503161000},"page":"151-153","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin"],"prefix":"10.1016","volume":"49","author":[{"given":"Saverio G.","family":"Parisi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Loregian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Andreis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Nannetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Cavinato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzo","family":"Scaggiante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Dal Bello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Messa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Cattelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Pal\u00f9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2016.06.020_bib0050","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/QAD.0000000000001020","article-title":"Interferon-free treatment with sofosbuvir\/daclatasvir achieves sustained virologic response in 100% of HIV\/hepatitis C virus-coinfected patients with advanced liver disease","volume":"30","author":"Mandorfer","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2016.06.020_bib0055","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchromb.2007.05.039","article-title":"Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection","volume":"856","author":"Loregian","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.ijid.2016.06.020_bib0060","unstructured":"Nannetti G, Messa L, Pagni S, Basso M, Pal\u00f9 G, Loregian A. Determination of the hepatitis C virus inhibitor daclatasvir and evaluation of its stability in human plasma by high performance liquid chromatography with UV detection. Manuscript in preparation."},{"key":"10.1016\/j.ijid.2016.06.020_bib0065","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2334-14-150","article-title":"Lower ribavirin biodisponibility in patients with HIV\u2013HCV coinfection in comparison with HCV monoinfected patients","volume":"14","author":"Hatu","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2016.06.020_bib0070","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)","volume":"63","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ijid.2016.06.020_bib0075","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.02788-14","article-title":"Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2016.06.020_bib0080","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2014.10.007","article-title":"Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 Infection","volume":"148","author":"Dore","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijid.2016.06.020_bib0085","unstructured":"Liverpool Hepatitis Drug Interactions website, 2010. Available at: http:\/\/www.hep-druginteractions.org\/. (accessed May 5, 2016)."},{"key":"10.1016\/j.ijid.2016.06.020_bib0090","unstructured":"American Association for the Study of Liver Diseases-Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C, 2016. http:\/\/www.hcvguidelines.org. (accessed May 5, 2016)."}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971216311055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971216311055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T15:52:35Z","timestamp":1536594755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971216311055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":9,"alternative-id":["S1201971216311055"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2016.06.020","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2016.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}